IBC 293
![]() | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H11N3O2 |
| Molar mass | 205.217 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
IBC 293 is an experimental drug which acts as a potent and selective agonist for the Hydroxycarboxylic acid receptor 3 (GPR109B), with good selectivity over the closely related HCA2/GPR109A receptor. It is used for studying the function of this receptor, and has been shown to activate neutrophils, demonstrating a role for HCA3 in immune system function.[1][2][3]
References
- ^ Semple G, Skinner PJ, Cherrier MC, Webb PJ, Sage CR, Tamura SY, et al. (February 2006). "1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b". Journal of Medicinal Chemistry. 49 (4): 1227–1230. doi:10.1021/jm051099t. PMID 16480258.
- ^ Boatman PD, Richman JG, Semple G (December 2008). "Nicotinic acid receptor agonists". Journal of Medicinal Chemistry. 51 (24): 7653–7662. doi:10.1021/jm800896z. PMID 18983141.
- ^ Forsman H, Li W, Levin NK, Karlsson R, Karlsson A, Dahlgren C, et al. (June 2025). "Activation and signaling characteristics of the hydroxy-carboxylic acid 3 receptor identified in human neutrophils through a microfluidic flow cell technique". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1872 (5) 119950. doi:10.1016/j.bbamcr.2025.119950. PMID 40194600.
